1
|
Chow Z, Johnson J, Chauhan A, Izumi T, Cavnar M, Weiss H, Anthony L, Evers B, Rychahou P. Inhibition of Ribonucleotide Reductase Subunit 2 (RRM2) Induces Radiosensitization in Gastroenteropancreatic Neuroendocrine Tumors. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
2
|
Abe K, Akutsu R, Ali A, Alt C, Andreopoulos C, Anthony L, Antonova M, Aoki S, Ariga A, Asada Y, Ashida Y, Atkin ET, Awataguchi Y, Ban S, Barbi M, Barker GJ, Barr G, Barrow D, Barry C, Batkiewicz-Kwasniak M, Beloshapkin A, Bench F, Berardi V, Berkman S, Berns L, Bhadra S, Bienstock S, Blondel A, Bolognesi S, Bourguille B, Boyd SB, Brailsford D, Bravar A, Bravo Berguño D, Bronner C, Bubak A, Buizza Avanzini M, Calcutt J, Campbell T, Cao S, Cartwright SL, Catanesi MG, Cervera A, Chappell A, Checchia C, Cherdack D, Chikuma N, Christodoulou G, Coleman J, Collazuol G, Cook L, Coplowe D, Cudd A, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Di Lodovico F, Dokania N, Dolan S, Doyle TA, Drapier O, Dumarchez J, Dunne P, Eklund L, Emery-Schrenk S, Ereditato A, Fernandez P, Feusels T, Finch AJ, Fiorentini GA, Fiorillo G, Francois C, Friend M, Fujii Y, Fujita R, Fukuda D, Fukuda R, Fukuda Y, Fusshoeller K, Gameil K, Giganti C, Golan T, Gonin M, Gorin A, Guigue M, Hadley DR, Haigh JT, Hamacher-Baumann P, Hartz M, Hasegawa T, Hastings NC, Hayashino T, Hayato Y, Hiramoto A, Hogan M, Holeczek J, Hong Van NT, Iacob F, Ichikawa AK, Ikeda M, Ishida T, Ishii T, Ishitsuka M, Iwamoto K, Izmaylov A, Jakkapu M, Jamieson B, Jenkins SJ, Jesús-Valls C, Jiang M, Johnson S, Jonsson P, Jung CK, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Kasetti SP, Kataoka Y, Katori T, Kato Y, Kearns E, Khabibullin M, Khotjantsev A, Kikawa T, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kormos LL, Koshio Y, Kostin A, Kowalik K, Kubo H, Kudenko Y, Kukita N, Kuribayashi S, Kurjata R, Kutter T, Kuze M, Labarga L, Lagoda J, Lamoureux M, Laveder M, Lawe M, Licciardi M, Lindner T, Litchfield RP, Liu SL, Li X, Longhin A, Ludovici L, Lu X, Lux T, Machado LN, Magaletti L, Mahn K, Malek M, Manly S, Maret L, Marino AD, Marti-Magro L, Martin JF, Maruyama T, Matsubara T, Matsushita K, Matveev V, Mavrokoridis K, Mazzucato E, McCarthy M, McCauley N, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Minamino A, Mineev O, Mine S, Miura M, Molina Bueno L, Moriyama S, Morrison J, Mueller TA, Munteanu L, Murphy S, Nagai Y, Nakadaira T, Nakahata M, Nakajima Y, Nakamura A, Nakamura KG, Nakamura K, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Ngoc TV, Niewczas K, Nishikawa K, Nishimura Y, Nonnenmacher TS, Nova F, Novella P, Nowak J, Nugent JC, O'Keeffe HM, O'Sullivan L, Odagawa T, Okumura K, Okusawa T, Oser SM, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Parker WC, Pasternak J, Paudyal P, Pavin M, Payne D, Penn GC, Pickering L, Pidcott C, Pintaudi G, Pinzon Guerra ES, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Pritchard A, Quilain B, Radermacher T, Radicioni E, Radics B, Ratoff PN, Reinherz-Aronis E, Riccio C, Rondio E, Roth S, Rubbia A, Ruggeri AC, Ruggles CA, Rychter A, Sakashita K, Sánchez F, Schloesser CM, Scholberg K, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaykina A, Shiozawa M, Shorrock W, Shvartsman A, Smirnov A, Smy M, Sobczyk JT, Sobel H, Soler FJP, Sonoda Y, Steinmann J, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tada M, Tajima M, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Tanaka S, Thompson LF, Toki W, Touramanis C, Towstego T, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Uno W, Vagins M, Valder S, Vallari Z, Vargas D, Vasseur G, Vilela C, Vinning WGS, Vladisavljevic T, Volkov VV, Wachala T, Walker J, Walsh JG, Wang Y, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Wood K, Wret C, Yamada Y, Yamamoto K, Yanagisawa C, Yang G, Yano T, Yasutome K, Yen S, Yershov N, Yokoyama M, Yoshida T, Yu M, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S, Zykova A. Search for Electron Antineutrino Appearance in a Long-Baseline Muon Antineutrino Beam. Phys Rev Lett 2020; 124:161802. [PMID: 32383902 DOI: 10.1103/physrevlett.124.161802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 02/26/2020] [Accepted: 03/25/2020] [Indexed: 06/11/2023]
Abstract
Electron antineutrino appearance is measured by the T2K experiment in an accelerator-produced antineutrino beam, using additional neutrino beam operation to constrain parameters of the Pontecorvo-Maki-Nakagawa-Sakata (PMNS) mixing matrix. T2K observes 15 candidate electron antineutrino events with a background expectation of 9.3 events. Including information from the kinematic distribution of observed events, the hypothesis of no electron antineutrino appearance is disfavored with a significance of 2.40σ and no discrepancy between data and PMNS predictions is found. A complementary analysis that introduces an additional free parameter which allows non-PMNS values of electron neutrino and antineutrino appearance also finds no discrepancy between data and PMNS predictions.
Collapse
Affiliation(s)
- K Abe
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - R Akutsu
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - A Ali
- Kyoto University, Department of Physics, Kyoto, Japan
| | - C Alt
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - C Andreopoulos
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - L Anthony
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Antonova
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - S Aoki
- Kobe University, Kobe, Japan
| | - A Ariga
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - Y Asada
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - Y Ashida
- Kyoto University, Department of Physics, Kyoto, Japan
| | - E T Atkin
- Imperial College London, Department of Physics, London, United Kingdom
| | - Y Awataguchi
- Tokyo Metropolitan University, Department of Physics, Tokyo, Japan
| | - S Ban
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Barbi
- University of Regina, Department of Physics, Regina, Saskatchewan, Canada
| | - G J Barker
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - G Barr
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - D Barrow
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - C Barry
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | | | - A Beloshapkin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Bench
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - V Berardi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - S Berkman
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - L Berns
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - S Bhadra
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - S Bienstock
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - A Blondel
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | | | - B Bourguille
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - S B Boyd
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - D Brailsford
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - A Bravar
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - D Bravo Berguño
- University Autonoma Madrid, Department of Theoretical Physics, Madrid, Spain
| | - C Bronner
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Bubak
- University of Silesia, Institute of Physics, Katowice, Poland
| | - M Buizza Avanzini
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Calcutt
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - T Campbell
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - S Cao
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - S L Cartwright
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - M G Catanesi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - A Cervera
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - A Chappell
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - C Checchia
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - D Cherdack
- University of Houston, Department of Physics, Houston, Texas, USA
| | - N Chikuma
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - G Christodoulou
- CERN European Organization for Nuclear Research, CH-1211 Genève 23, Switzerland
| | - J Coleman
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - G Collazuol
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - L Cook
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - D Coplowe
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - A Cudd
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - A Dabrowska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - G De Rosa
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - T Dealtry
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - P F Denner
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - S R Dennis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - C Densham
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - F Di Lodovico
- King's College London, Department of Physics, Strand, London WC2R 2LS, United Kingdom
| | - N Dokania
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - S Dolan
- CERN European Organization for Nuclear Research, CH-1211 Genève 23, Switzerland
| | - T A Doyle
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - O Drapier
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Dumarchez
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - P Dunne
- Imperial College London, Department of Physics, London, United Kingdom
| | - L Eklund
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | | | - A Ereditato
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - P Fernandez
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - T Feusels
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - A J Finch
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - G A Fiorentini
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - G Fiorillo
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - C Francois
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - M Friend
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Fujii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - R Fujita
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - D Fukuda
- Okayama University, Department of Physics, Okayama, Japan
| | - R Fukuda
- Tokyo University of Science, Faculty of Science and Technology, Department of Physics, Noda, Chiba, Japan
| | - Y Fukuda
- Miyagi University of Education, Department of Physics, Sendai, Japan
| | - K Fusshoeller
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - K Gameil
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - C Giganti
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - T Golan
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - M Gonin
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - A Gorin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Guigue
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - D R Hadley
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - J T Haigh
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | | | - M Hartz
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- TRIUMF, Vancouver, British Columbia, Canada
| | - T Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - N C Hastings
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Hayashino
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Hayato
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Hiramoto
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Hogan
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - J Holeczek
- University of Silesia, Institute of Physics, Katowice, Poland
| | - N T Hong Van
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
- International Centre of Physics, Institute of Physics (IOP), Vietnam Academy of Science and Technology (VAST), 10 Dao Tan, Ba Dinh, Hanoi, Vietnam
| | - F Iacob
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - A K Ichikawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Ikeda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Ishii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Ishitsuka
- Tokyo University of Science, Faculty of Science and Technology, Department of Physics, Noda, Chiba, Japan
| | - K Iwamoto
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - A Izmaylov
- IFIC (CSIC & University of Valencia), Valencia, Spain
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Jakkapu
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - B Jamieson
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - S J Jenkins
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - C Jesús-Valls
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - M Jiang
- Kyoto University, Department of Physics, Kyoto, Japan
| | - S Johnson
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - P Jonsson
- Imperial College London, Department of Physics, London, United Kingdom
| | - C K Jung
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - M Kabirnezhad
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - A C Kaboth
- Royal Holloway University of London, Department of Physics, Egham, Surrey, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - T Kajita
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - H Kakuno
- Tokyo Metropolitan University, Department of Physics, Tokyo, Japan
| | - J Kameda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - D Karlen
- TRIUMF, Vancouver, British Columbia, Canada
- University of Victoria, Department of Physics and Astronomy, Victoria, British Columbia, Canada
| | - S P Kasetti
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - Y Kataoka
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Katori
- King's College London, Department of Physics, Strand, London WC2R 2LS, United Kingdom
| | - Y Kato
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - E Kearns
- Boston University, Department of Physics, Boston, Massachusetts, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T Kikawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - H Kim
- Osaka City University, Department of Physics, Osaka, Japan
| | - J Kim
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - S King
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - J Kisiel
- University of Silesia, Institute of Physics, Katowice, Poland
| | - A Knight
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - A Knox
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - T Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - L Koch
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - T Koga
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - A Konaka
- TRIUMF, Vancouver, British Columbia, Canada
| | - L L Kormos
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - Y Koshio
- Okayama University, Department of Physics, Okayama, Japan
| | - A Kostin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Kowalik
- National Centre for Nuclear Research, Warsaw, Poland
| | - H Kubo
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - N Kukita
- Osaka City University, Department of Physics, Osaka, Japan
| | - S Kuribayashi
- Kyoto University, Department of Physics, Kyoto, Japan
| | - R Kurjata
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - T Kutter
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - M Kuze
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - L Labarga
- University Autonoma Madrid, Department of Theoretical Physics, Madrid, Spain
| | - J Lagoda
- National Centre for Nuclear Research, Warsaw, Poland
| | - M Lamoureux
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - M Laveder
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - M Lawe
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - M Licciardi
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - T Lindner
- TRIUMF, Vancouver, British Columbia, Canada
| | - R P Litchfield
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - S L Liu
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - X Li
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - A Longhin
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - L Ludovici
- INFN Sezione di Roma and Università di Roma "La Sapienza", Roma, Italy
| | - X Lu
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - T Lux
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - L N Machado
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - L Magaletti
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - K Mahn
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - M Malek
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - S Manly
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - L Maret
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - A D Marino
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - L Marti-Magro
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J F Martin
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - T Maruyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Matsubara
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Matsushita
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - V Matveev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Mavrokoridis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | | | - M McCarthy
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - N McCauley
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - K S McFarland
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - C McGrew
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - A Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C Metelko
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Mezzetto
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - A Minamino
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - O Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S Mine
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
| | - M Miura
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - L Molina Bueno
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - S Moriyama
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J Morrison
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - Th A Mueller
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - L Munteanu
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - S Murphy
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - Y Nagai
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - T Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Nakahata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - Y Nakajima
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Nakamura
- Okayama University, Department of Physics, Okayama, Japan
| | - K G Nakamura
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - S Nakayama
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Nakaya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Nakayoshi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - C Nantais
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - T V Ngoc
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
| | - K Niewczas
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - K Nishikawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Nishimura
- Keio University, Department of Physics, Kanagawa, Japan
| | - T S Nonnenmacher
- Imperial College London, Department of Physics, London, United Kingdom
| | - F Nova
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - P Novella
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - J Nowak
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - J C Nugent
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - H M O'Keeffe
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - L O'Sullivan
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - T Odagawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Okumura
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - T Okusawa
- Osaka City University, Department of Physics, Osaka, Japan
| | - S M Oser
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - R A Owen
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - Y Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - V Palladino
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - J L Palomino
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - V Paolone
- University of Pittsburgh, Department of Physics and Astronomy, Pittsburgh, Pennsylvania, USA
| | - W C Parker
- Royal Holloway University of London, Department of Physics, Egham, Surrey, United Kingdom
| | - J Pasternak
- Imperial College London, Department of Physics, London, United Kingdom
| | - P Paudyal
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Pavin
- TRIUMF, Vancouver, British Columbia, Canada
| | - D Payne
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - G C Penn
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - L Pickering
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - C Pidcott
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - G Pintaudi
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - E S Pinzon Guerra
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - C Pistillo
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - B Popov
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - K Porwit
- University of Silesia, Institute of Physics, Katowice, Poland
| | | | - A Pritchard
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - B Quilain
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - T Radermacher
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - E Radicioni
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - B Radics
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - P N Ratoff
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - E Reinherz-Aronis
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - C Riccio
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - E Rondio
- National Centre for Nuclear Research, Warsaw, Poland
| | - S Roth
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - A Rubbia
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - A C Ruggeri
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - C A Ruggles
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - A Rychter
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - K Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - F Sánchez
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - C M Schloesser
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - K Scholberg
- Duke University, Department of Physics, Durham, North Carolina, USA
| | - J Schwehr
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - M Scott
- Imperial College London, Department of Physics, London, United Kingdom
| | - Y Seiya
- Osaka City University, Department of Physics, Osaka, Japan
| | - T Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - H Sekiya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - D Sgalaberna
- CERN European Organization for Nuclear Research, CH-1211 Genève 23, Switzerland
| | - R Shah
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - A Shaikhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Shaker
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - A Shaykina
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Shiozawa
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - W Shorrock
- Imperial College London, Department of Physics, London, United Kingdom
| | - A Shvartsman
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Smirnov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Smy
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
| | - J T Sobczyk
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - H Sobel
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - F J P Soler
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - Y Sonoda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J Steinmann
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - S Suvorov
- IRFU, CEA Saclay, Gif-sur-Yvette, France
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - S Y Suzuki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Suzuki
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - A A Sztuc
- Imperial College London, Department of Physics, London, United Kingdom
| | - M Tada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Tajima
- Kyoto University, Department of Physics, Kyoto, Japan
| | - A Takeda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - Y Takeuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kobe University, Kobe, Japan
| | - H K Tanaka
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - H A Tanaka
- SLAC National Accelerator Laboratory, Stanford University, Menlo Park, California, USA
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - S Tanaka
- Osaka City University, Department of Physics, Osaka, Japan
| | - L F Thompson
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - W Toki
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - C Touramanis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - T Towstego
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - K M Tsui
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - T Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Tzanov
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - Y Uchida
- Imperial College London, Department of Physics, London, United Kingdom
| | - W Uno
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Vagins
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - S Valder
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - Z Vallari
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - D Vargas
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - G Vasseur
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - C Vilela
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - W G S Vinning
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - T Vladisavljevic
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - V V Volkov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T Wachala
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Walker
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - J G Walsh
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - Y Wang
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - D Wark
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - M O Wascko
- Imperial College London, Department of Physics, London, United Kingdom
| | - A Weber
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - R Wendell
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M J Wilking
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - C Wilkinson
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - J R Wilson
- King's College London, Department of Physics, Strand, London WC2R 2LS, United Kingdom
| | - R J Wilson
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - K Wood
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - C Wret
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - Y Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Yamamoto
- Osaka City University, Department of Physics, Osaka, Japan
| | - C Yanagisawa
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - G Yang
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - T Yano
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - K Yasutome
- Kyoto University, Department of Physics, Kyoto, Japan
| | - S Yen
- TRIUMF, Vancouver, British Columbia, Canada
| | - N Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Yokoyama
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - T Yoshida
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - M Yu
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - A Zalewska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Zalipska
- National Centre for Nuclear Research, Warsaw, Poland
| | - K Zaremba
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - G Zarnecki
- National Centre for Nuclear Research, Warsaw, Poland
| | - M Ziembicki
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - E D Zimmerman
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - M Zito
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - S Zsoldos
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - A Zykova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
3
|
Abe K, Akutsu R, Ali A, Alt C, Andreopoulos C, Anthony L, Antonova M, Aoki S, Ariga A, Arihara T, Asada Y, Ashida Y, Atkin ET, Awataguchi Y, Ban S, Barbi M, Barker GJ, Barr G, Barrow D, Barry C, Batkiewicz-Kwasniak M, Beloshapkin A, Bench F, Berardi V, Berkman S, Berns L, Bhadra S, Bienstock S, Blondel A, Bolognesi S, Bourguille B, Boyd SB, Brailsford D, Bravar A, Berguño DB, Bronner C, Bubak A, Avanzini MB, Calcutt J, Campbell T, Cao S, Cartwright SL, Catanesi MG, Cervera A, Chappell A, Checchia C, Cherdack D, Chikuma N, Cicerchia M, Christodoulou G, Coleman J, Collazuol G, Cook L, Coplowe D, Cudd A, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Di Lodovico F, Dokania N, Dolan S, Doyle TA, Drapier O, Dumarchez J, Dunne P, Eguchi A, Eklund L, Emery-Schrenk S, Ereditato A, Fernandez P, Feusels T, Finch AJ, Fiorentini GA, Fiorillo G, Francois C, Friend M, Fujii Y, Fujita R, Fukuda D, Fukuda R, Fukuda Y, Fusshoeller K, Gameil K, Giganti C, Golan T, Gonin M, Gorin A, Guigue M, Hadley DR, Haigh JT, Hamacher-Baumann P, Hartz M, Hasegawa T, Hassani S, Hastings NC, Hayashino T, Hayato Y, Hiramoto A, Hogan M, Holeczek J, Hong Van NT, Iacob F, Ichikawa AK, Ikeda M, Ishida T, Ishii T, Ishitsuka M, Iwamoto K, Izmaylov A, Jakkapu M, Jamieson B, Jenkins SJ, Jesús-Valls C, Jiang M, Johnson S, Jonsson P, Jung CK, Junjie X, Jurj PB, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Kasetti SP, Kataoka Y, Katori T, Kato Y, Kearns E, Khabibullin M, Khotjantsev A, Kikawa T, Kikutani H, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kormos LL, Koshio Y, Kostin A, Kowalik K, Kubo H, Kudenko Y, Kukita N, Kuribayashi S, Kurjata R, Kutter T, Kuze M, Labarga L, Lagoda J, Lamoureux M, Laveder M, Lawe M, Licciardi M, Lindner T, Litchfield RP, Liu SL, Li X, Longhin A, Ludovici L, Lu X, Lux T, Machado LN, Magaletti L, Mahn K, Malek M, Manly S, Maret L, Marino AD, Marti-Magro L, Martin JF, Maruyama T, Matsubara T, Matsushita K, Matveev V, Mavrokoridis K, Mazzucato E, McCarthy M, McCauley N, McElwee J, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Minamino A, Mineev O, Mine S, Miura M, Bueno LM, Moriyama S, Morrison J, Mueller TA, Munteanu L, Murphy S, Nagai Y, Nakadaira T, Nakahata M, Nakajima Y, Nakamura A, Nakamura KG, Nakamura K, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Naseby CER, Ngoc TV, Niewczas K, Nishikawa K, Nishimura Y, Noah E, Nonnenmacher TS, Nova F, Novella P, Nowak J, Nugent JC, O’Keeffe HM, O’Sullivan L, Odagawa T, Okumura K, Okusawa T, Oser SM, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Pari M, Parker WC, Parsa S, Pasternak J, Paudyal P, Pavin M, Payne D, Penn GC, Pickering L, Pidcott C, Pintaudi G, Guerra ESP, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Pritchard A, Quilain B, Radermacher T, Radicioni E, Radics B, Ratoff PN, Reinherz-Aronis E, Riccio C, Rondio E, Roth S, Rubbia A, Ruggeri AC, Ruggles CA, Rychter A, Sakashita K, Sánchez F, Santucci G, Schloesser CM, Scholberg K, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaykina A, Shiozawa M, Shorrock W, Shvartsman A, Smirnov A, Smy M, Sobczyk JT, Sobel H, Soler FJP, Sonoda Y, Steinmann J, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tada M, Tajima M, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Tanaka S, Thompson LF, Toki W, Touramanis C, Towstego T, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Uno W, Vagins M, Valder S, Vallari Z, Vargas D, Vasseur G, Vilela C, Vinning WGS, Vladisavljevic T, Volkov VV, Wachala T, Walker J, Walsh JG, Wang Y, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Wood K, Wret C, Yamada Y, Yamamoto K, Yanagisawa C, Yang G, Yano T, Yasutome K, Yen S, Yershov N, Yokoyama M, Yoshida T, Yu M, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S, Zykova A. Constraint on the matter–antimatter symmetry-violating phase in neutrino oscillations. Nature 2020; 580:339-344. [DOI: 10.1038/s41586-020-2177-0] [Citation(s) in RCA: 188] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 03/03/2020] [Indexed: 11/09/2022]
|
4
|
Gabriel G, Anthony L, Chauhan A, El Khouli R. 3:45 PM Abstract No. 232 Efficacy of transarterial bland embolization with concurrent everolimus (EveroEmbo) in the treatment of hepatic metastatic neuroendocrine tumors. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
5
|
Abe K, Akutsu R, Ali A, Amey J, Andreopoulos C, Anthony L, Antonova M, Aoki S, Ariga A, Ashida Y, Azuma Y, Ban S, Barbi M, Barker GJ, Barr G, Barry C, Batkiewicz M, Bench F, Berardi V, Berkman S, Berner RM, Berns L, Bhadra S, Bienstock S, Blondel A, Bolognesi S, Bourguille B, Boyd SB, Brailsford D, Bravar A, Bronner C, Buizza Avanzini M, Calcutt J, Campbell T, Cao S, Cartwright SL, Catanesi MG, Cervera A, Chappell A, Checchia C, Cherdack D, Chikuma N, Christodoulou G, Coleman J, Collazuol G, Coplowe D, Cudd A, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Di Lodovico F, Dokania N, Dolan S, Drapier O, Duffy KE, Dumarchez J, Dunne P, Emery-Schrenk S, Ereditato A, Fernandez P, Feusels T, Finch AJ, Fiorentini GA, Fiorillo G, Francois C, Friend M, Fujii Y, Fujita R, Fukuda D, Fukuda Y, Gameil K, Giganti C, Gizzarelli F, Golan T, Gonin M, Hadley DR, Haegel L, Haigh JT, Hamacher-Baumann P, Hansen D, Harada J, Hartz M, Hasegawa T, Hastings NC, Hayashino T, Hayato Y, Hiramoto A, Hogan M, Holeczek J, Hosomi F, Ichikawa AK, Ikeda M, Imber J, Inoue T, Intonti RA, Ishida T, Ishii T, Ishitsuka M, Iwamoto K, Izmaylov A, Jamieson B, Jiang M, Johnson S, Jonsson P, Jung CK, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Katori T, Kato Y, Kearns E, Khabibullin M, Khotjantsev A, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Koller PP, Konaka A, Kormos LL, Koshio Y, Kowalik K, Kubo H, Kudenko Y, Kurjata R, Kutter T, Kuze M, Labarga L, Lagoda J, Lamoureux M, Lasorak P, Laveder M, Lawe M, Licciardi M, Lindner T, Liptak ZJ, Litchfield RP, Li X, Longhin A, Lopez JP, Lou T, Ludovici L, Lu X, Magaletti L, Mahn K, Malek M, Manly S, Maret L, Marino AD, Martin JF, Martins P, Maruyama T, Matsubara T, Matveev V, Mavrokoridis K, Ma WY, Mazzucato E, McCarthy M, McCauley N, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Minamino A, Mineev O, Mine S, Missert A, Miura M, Moriyama S, Morrison J, Mueller TA, Murphy S, Nagai Y, Nakadaira T, Nakahata M, Nakajima Y, Nakamura KG, Nakamura K, Nakamura KD, Nakanishi Y, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Nielsen C, Niewczas K, Nishikawa K, Nishimura Y, Nonnenmacher TS, Novella P, Nowak J, O'Keeffe HM, O'Sullivan L, Okumura K, Okusawa T, Oryszczak W, Oser SM, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Paudyal P, Pavin M, Payne D, Pickering L, Pidcott C, Pinzon Guerra ES, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Pritchard A, Quilain B, Radermacher T, Radicioni E, Ratoff PN, Reinherz-Aronis E, Riccio C, Rondio E, Rossi B, Roth S, Rubbia A, Ruggeri AC, Rychter A, Sakashita K, Sánchez F, Sasaki S, Scantamburlo E, Scholberg K, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaw D, Shiozawa M, Smirnov A, Smy M, Sobczyk JT, Sobel H, Sonoda Y, Steinmann J, Stewart T, Stowell P, Suda Y, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tacik R, Tada M, Takeda A, Takeuchi Y, Tamura R, Tanaka HK, Tanaka HA, Thakore T, Thompson LF, Toki W, Touramanis C, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Uno W, Vagins M, Vallari Z, Vasseur G, Vilela C, Vladisavljevic T, Volkov VV, Wachala T, Walker J, Wang Y, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Wret C, Yamada Y, Yamamoto K, Yamasu S, Yanagisawa C, Yang G, Yano T, Yasutome K, Yen S, Yershov N, Yokoyama M, Yoshida T, Yu M, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S, Zykova A. Search for CP Violation in Neutrino and Antineutrino Oscillations by the T2K Experiment with 2.2×10^{21} Protons on Target. Phys Rev Lett 2018; 121:171802. [PMID: 30411920 DOI: 10.1103/physrevlett.121.171802] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/2018] [Indexed: 06/08/2023]
Abstract
The T2K experiment measures muon neutrino disappearance and electron neutrino appearance in accelerator-produced neutrino and antineutrino beams. With an exposure of 14.7(7.6)×10^{20} protons on target in the neutrino (antineutrino) mode, 89 ν_{e} candidates and seven anti-ν_{e} candidates are observed, while 67.5 and 9.0 are expected for δ_{CP}=0 and normal mass ordering. The obtained 2σ confidence interval for the CP-violating phase, δ_{CP}, does not include the CP-conserving cases (δ_{CP}=0, π). The best-fit values of other parameters are sin^{2}θ_{23}=0.526_{-0.036}^{+0.032} and Δm_{32}^{2}=2.463_{-0.070}^{+0.071}×10^{-3} eV^{2}/c^{4}.
Collapse
Affiliation(s)
- K Abe
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - R Akutsu
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - A Ali
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - J Amey
- Imperial College London, Department of Physics, London, United Kingdom
| | - C Andreopoulos
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - L Anthony
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Antonova
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - S Aoki
- Kobe University, Kobe, Japan
| | - A Ariga
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - Y Ashida
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Azuma
- Osaka City University, Department of Physics, Osaka, Japan
| | - S Ban
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Barbi
- University of Regina, Department of Physics, Regina, Saskatchewan, Canada
| | - G J Barker
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - G Barr
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - C Barry
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Batkiewicz
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - F Bench
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - V Berardi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - S Berkman
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - R M Berner
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - L Berns
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - S Bhadra
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - S Bienstock
- UPMC, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - A Blondel
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | | | - B Bourguille
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona), Spain
| | - S B Boyd
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - D Brailsford
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - A Bravar
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - C Bronner
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - M Buizza Avanzini
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Calcutt
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - T Campbell
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - S Cao
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - S L Cartwright
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - M G Catanesi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - A Cervera
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - A Chappell
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - C Checchia
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - D Cherdack
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - N Chikuma
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - G Christodoulou
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - J Coleman
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - G Collazuol
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - D Coplowe
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - A Cudd
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - A Dabrowska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - G De Rosa
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - T Dealtry
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - P F Denner
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - S R Dennis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - C Densham
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - F Di Lodovico
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - N Dokania
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - S Dolan
- IRFU, CEA Saclay, Gif-sur-Yvette, France
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - O Drapier
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - K E Duffy
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - J Dumarchez
- UPMC, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - P Dunne
- Imperial College London, Department of Physics, London, United Kingdom
| | | | - A Ereditato
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - P Fernandez
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - T Feusels
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - A J Finch
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - G A Fiorentini
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - G Fiorillo
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - C Francois
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - M Friend
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Fujii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - R Fujita
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - D Fukuda
- Okayama University, Department of Physics, Okayama, Japan
| | - Y Fukuda
- Miyagi University of Education, Department of Physics, Sendai, Japan
| | - K Gameil
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - C Giganti
- UPMC, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | | | - T Golan
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - M Gonin
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - D R Hadley
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - L Haegel
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - J T Haigh
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | | | - D Hansen
- University of Pittsburgh, Department of Physics and Astronomy, Pittsburgh, Pennsylvania, USA
| | - J Harada
- Osaka City University, Department of Physics, Osaka, Japan
| | - M Hartz
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- TRIUMF, Vancouver, British Columbia, Canada
| | - T Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - N C Hastings
- University of Regina, Department of Physics, Regina, Saskatchewan, Canada
| | - T Hayashino
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Hayato
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Hiramoto
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Hogan
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - J Holeczek
- University of Silesia, Institute of Physics, Katowice, Poland
| | - F Hosomi
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - A K Ichikawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Ikeda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J Imber
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - T Inoue
- Osaka City University, Department of Physics, Osaka, Japan
| | - R A Intonti
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - T Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Ishii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Ishitsuka
- Tokyo University of Science, Faculty of Science and Technology, Department of Physics, Noda, Chiba, Japan
| | - K Iwamoto
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - A Izmaylov
- IFIC (CSIC and University of Valencia), Valencia, Spain
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - B Jamieson
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - M Jiang
- Kyoto University, Department of Physics, Kyoto, Japan
| | - S Johnson
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - P Jonsson
- Imperial College London, Department of Physics, London, United Kingdom
| | - C K Jung
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - M Kabirnezhad
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - A C Kaboth
- Royal Holloway University of London, Department of Physics, Egham, Surrey, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - T Kajita
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - H Kakuno
- Tokyo Metropolitan University, Department of Physics, Tokyo, Japan
| | - J Kameda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - D Karlen
- TRIUMF, Vancouver, British Columbia, Canada
- University of Victoria, Department of Physics and Astronomy, Victoria, British Columbia, Canada
| | - T Katori
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - Y Kato
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - E Kearns
- Boston University, Department of Physics, Boston, Massachusetts, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - H Kim
- Osaka City University, Department of Physics, Osaka, Japan
| | - J Kim
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - S King
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - J Kisiel
- University of Silesia, Institute of Physics, Katowice, Poland
| | - A Knight
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - A Knox
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - T Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - L Koch
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - T Koga
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - P P Koller
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - A Konaka
- TRIUMF, Vancouver, British Columbia, Canada
| | - L L Kormos
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - Y Koshio
- Okayama University, Department of Physics, Okayama, Japan
| | - K Kowalik
- National Centre for Nuclear Research, Warsaw, Poland
| | - H Kubo
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - R Kurjata
- Warsaw University of Technology, Institute of Radioelectronics, Warsaw, Poland
| | - T Kutter
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - M Kuze
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - L Labarga
- University Autonoma Madrid, Department of Theoretical Physics, Madrid, Spain
| | - J Lagoda
- National Centre for Nuclear Research, Warsaw, Poland
| | | | - P Lasorak
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - M Laveder
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - M Lawe
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - M Licciardi
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - T Lindner
- TRIUMF, Vancouver, British Columbia, Canada
| | - Z J Liptak
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - R P Litchfield
- Imperial College London, Department of Physics, London, United Kingdom
| | - X Li
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - A Longhin
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - J P Lopez
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - T Lou
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - L Ludovici
- INFN Sezione di Roma and Università di Roma "La Sapienza," Roma, Italy
| | - X Lu
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - L Magaletti
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - K Mahn
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - M Malek
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - S Manly
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - L Maret
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - A D Marino
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - J F Martin
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - P Martins
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - T Maruyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Matsubara
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - V Matveev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Mavrokoridis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - W Y Ma
- Imperial College London, Department of Physics, London, United Kingdom
| | | | - M McCarthy
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - N McCauley
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - K S McFarland
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - C McGrew
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - A Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C Metelko
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Mezzetto
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - A Minamino
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - O Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S Mine
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
| | - A Missert
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - M Miura
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - S Moriyama
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J Morrison
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - Th A Mueller
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - S Murphy
- ETH Zurich, Institute for Particle Physics, Zurich, Switzerland
| | - Y Nagai
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - T Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Nakahata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - Y Nakajima
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - K G Nakamura
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - K D Nakamura
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Nakanishi
- Kyoto University, Department of Physics, Kyoto, Japan
| | - S Nakayama
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Nakaya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Nakayoshi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - C Nantais
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - C Nielsen
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - K Niewczas
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - K Nishikawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Nishimura
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - T S Nonnenmacher
- Imperial College London, Department of Physics, London, United Kingdom
| | - P Novella
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - J Nowak
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - H M O'Keeffe
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - L O'Sullivan
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - K Okumura
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - T Okusawa
- Osaka City University, Department of Physics, Osaka, Japan
| | - W Oryszczak
- University of Warsaw, Faculty of Physics, Warsaw, Poland
| | - S M Oser
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - R A Owen
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - Y Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - V Palladino
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - J L Palomino
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - V Paolone
- University of Pittsburgh, Department of Physics and Astronomy, Pittsburgh, Pennsylvania, USA
| | - P Paudyal
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Pavin
- TRIUMF, Vancouver, British Columbia, Canada
| | - D Payne
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - L Pickering
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - C Pidcott
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - E S Pinzon Guerra
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - C Pistillo
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - B Popov
- UPMC, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - K Porwit
- University of Silesia, Institute of Physics, Katowice, Poland
| | | | - A Pritchard
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - B Quilain
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - T Radermacher
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - E Radicioni
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - P N Ratoff
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - E Reinherz-Aronis
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - C Riccio
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - E Rondio
- National Centre for Nuclear Research, Warsaw, Poland
| | - B Rossi
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - S Roth
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - A Rubbia
- ETH Zurich, Institute for Particle Physics, Zurich, Switzerland
| | - A C Ruggeri
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - A Rychter
- Warsaw University of Technology, Institute of Radioelectronics, Warsaw, Poland
| | - K Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - F Sánchez
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - S Sasaki
- Tokyo Metropolitan University, Department of Physics, Tokyo, Japan
| | - E Scantamburlo
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - K Scholberg
- Duke University, Department of Physics, Durham, North Carolina, USA
| | - J Schwehr
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - M Scott
- Imperial College London, Department of Physics, London, United Kingdom
| | - Y Seiya
- Osaka City University, Department of Physics, Osaka, Japan
| | - T Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - H Sekiya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - D Sgalaberna
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - R Shah
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - A Shaikhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Shaker
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - D Shaw
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - M Shiozawa
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Smirnov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Smy
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
| | - J T Sobczyk
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - H Sobel
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - Y Sonoda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J Steinmann
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - T Stewart
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - P Stowell
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - Y Suda
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - S Suvorov
- IRFU, CEA Saclay, Gif-sur-Yvette, France
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - S Y Suzuki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Suzuki
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - A A Sztuc
- Imperial College London, Department of Physics, London, United Kingdom
| | - R Tacik
- University of Regina, Department of Physics, Regina, Saskatchewan, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - M Tada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - A Takeda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - Y Takeuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kobe University, Kobe, Japan
| | - R Tamura
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - H K Tanaka
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - H A Tanaka
- SLAC National Accelerator Laboratory, Stanford University, Menlo Park, California, USA
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - T Thakore
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - L F Thompson
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - W Toki
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - C Touramanis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - K M Tsui
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - T Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Tzanov
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - Y Uchida
- Imperial College London, Department of Physics, London, United Kingdom
| | - W Uno
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Vagins
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - Z Vallari
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - G Vasseur
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - C Vilela
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - T Vladisavljevic
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - V V Volkov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T Wachala
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Walker
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - Y Wang
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - D Wark
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - M O Wascko
- Imperial College London, Department of Physics, London, United Kingdom
| | - A Weber
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - R Wendell
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M J Wilking
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - C Wilkinson
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - J R Wilson
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - R J Wilson
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - C Wret
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - Y Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Yamamoto
- Osaka City University, Department of Physics, Osaka, Japan
| | - S Yamasu
- Okayama University, Department of Physics, Okayama, Japan
| | - C Yanagisawa
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - G Yang
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - T Yano
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - K Yasutome
- Kyoto University, Department of Physics, Kyoto, Japan
| | - S Yen
- TRIUMF, Vancouver, British Columbia, Canada
| | - N Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Yokoyama
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - T Yoshida
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - M Yu
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - A Zalewska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Zalipska
- National Centre for Nuclear Research, Warsaw, Poland
| | - K Zaremba
- Warsaw University of Technology, Institute of Radioelectronics, Warsaw, Poland
| | - G Zarnecki
- National Centre for Nuclear Research, Warsaw, Poland
| | - M Ziembicki
- Warsaw University of Technology, Institute of Radioelectronics, Warsaw, Poland
| | - E D Zimmerman
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - M Zito
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - S Zsoldos
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - A Zykova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
6
|
Kenworthy L, Childress D, Verbalis A, Armour A, Werner M, Troxel M, Anthony L. Executive Function - 2
Randomized Controlled Trial of e-Unstuck On-Line Parent Training Modules Versus In-Person Training. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy060.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Affiliation(s)
- A Chauhan
- Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, USA
| | - L Anthony
- Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, USA
| |
Collapse
|
8
|
Chauhan A, Mynt Z, Arnold S, Grant B, Anthony L. P2.07-051 Immune Checkpoint Associated Cardiotoxicity: An Update. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Myint Z, Chauhan A, Arnold S, Anthony L. P3.15-010 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Natural History of the Disease Progression and Management. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Hörsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Öberg K, Warner R, Kunz P, Grande Pulido E, Valle J, Dillon J, Lapuerta P, Banks P, Jackson S, Pavel M. Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx368.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Aggarwal R, Mansfield A, Beltran H, Farago A, Hann C, Kaye F, Lewis K, Niu J, Richey S, Smith D, Soares H, Spira A, Taylor M, Waqar S, Lally S, Rossi M, Saunders L, Dylla S, Kavalerchik E, Anthony L. Preliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx368.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Lapuerta P, Kulke M, Caplin M, Bergsland E, Anthony L, Öberg K, Pavel M, Hörsch D, O'Dorisio T, Dillon J, Kassler-Taub K, Jiang W. Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx368.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
13
|
Chauhan A, Burkeen G, Houranieh J, Arnold S, Anthony L. Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature. Ann Oncol 2017; 28:2034-2038. [DOI: 10.1093/annonc/mdx213] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Kulke M, Hörsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Bohas CL, Kunz P, Grande E, Valle J, Lapuerta P, Banks P, Jackson S, Jiang W, Biran T, Pavel M. Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw369.07] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Kulke M, Horsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Grande E, Valle J, Fleming D, Lapuerta P, Banks P, Jackson S, Wheeler D, Zambrowicz B, Sands A, Pavel M. 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31951-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Lennon S, Anthony L, Burnell S, Ventoruzzo S, Bradnam L. A falls prevention program for people with ms who fall: a feasibility pre-post intervention design. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Chauhan A, Wang YZ, Hall MA, Boudreaux JP, Woltering E, Anthony L. IN VITRO CHEMOTHERAPY PROFILING OF WELL-DIFFERENTIATED MIDGUT NEUROENDOCRINE TUMORS (NETS) BASED ON INDIVIDUAL PATIENT TUMOR BIOMARKERS ANALYSIS. J La State Med Soc 2015; 167:149. [PMID: 27159467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
BACKGROUND Midgut neuroendocrine tumors (NETs) are rare malignancies with indolent clinical courses. In general, they are well-differentiated with most tumor cells in the G0 phase of the cell cycle, consistent with the poor response rate of NETs to chemotherapy in vivo. We hypothesize that insults, such as surgery, can drive NET cells from G0 into S phase and that biomarker analysis of individual patient tumors harvested and grown in the lab will provide useful practical guide for future intra and post-operative adjuvant therapy. METHODS 97 well-differentiated midgut NET patients underwent cytoreductive surgery at our institution between May/2012 and October/2012. 148 surgical specimens were collected and submitted to a single commercial lab for processing. Primary tumors, lymph nodes and liver metastases were harvested and cultured. Their ribonucleic acids (RNA) were then extracted to analyze the expressivity, a total of 88 different biomarkers. Based on our patients' specific tumor biomarker expressivity and known correlations between 36 anti-neoplastic agents with their linked biomarkers, recommendations were reported as clinically beneficial or non-beneficial. RESULTS A total of 148 specimens from 97 patients were tested. In four of the 97 patients, no clinically beneficial chemotherapy agent could be identified. Among the remaining 93 patients, the top three agents that are most likely to be clinically beneficial are: fluorouracil, cisplatin and carboplatin. These were reported to be clinically beneficial in 135/148 (91.2%), 103/148 (69.6%), and 103/148 (69.6%) patients respectively. CONCLUSIONS Midgut NETs are slow growing tumors which are chemotherapeutically inert owing to the fact that most of the tumor cells are in G0 cell cycle. Surgical insult drives NET cells into active synthetic phase where they begin to express biomarkers specific to their tumor cells. Analysis of these biomarkers guides further potential beneficial therapy based on the current known associations among biomarkers and chemotherapy agents. These results must then be compared and confirmed against a direct in-vitro chemo sensitivity assessment conducted simultaneously on the same patients.
Collapse
Affiliation(s)
- A Chauhan
- Department of Internal Medicine, LSU Health Sciences Center, New Orleans, Louisiana
| | - Y Z Wang
- Department of Internal Medicine, LSU Health Sciences Center, New Orleans, Louisiana
| | - M A Hall
- Department of Internal Medicine, LSU Health Sciences Center, New Orleans, Louisiana
| | - J P Boudreaux
- Department of Internal Medicine, LSU Health Sciences Center, New Orleans, Louisiana
| | - E Woltering
- Department of Internal Medicine, LSU Health Sciences Center, New Orleans, Louisiana
| | - L Anthony
- University of Kentucky, Lexington, Kentucky
| |
Collapse
|
18
|
Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 2008; 99:722-6. [PMID: 18728662 PMCID: PMC2528148 DOI: 10.1038/sj.bjc.6604541] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Prolonged infusions have been shown to be safer and potentially more effective than bolus regimens of 5-fluorouracil (5-FU) as treatment for metastatic colorectal cancer (mCRC). However, infusional 5-FU requires central venous access and costly infusion pumps. Oral fluoropyrimidines enable longer exposures to 5-FU with increased convenience. Tegafur–uracil (UFT) with leucovorin (LV) given thrice daily has improved safety plus comparable survival and response rates to bolus 5-FU/LV. We conducted a phase II clinical study in 98 patients with mCRC to evaluate if UFT with LV given twice daily provided comparable time to progression (TTP), efficacy and tolerability to that reported for thrice daily in two phase III clinical studies. Secondary objectives included overall response rate (ORR) and overall survival (OS). Median TTP was 3.8 months, when compared with 3.5 months for thrice daily. The ORR (11%) and median OS (12.8 months) with twice daily administration were similar to that of thrice daily administration (12% and 12.4 months). The incidence of grade 3/4 treatment-related diarrhoea was 30% on the twice daily and 21% on the thrice daily schedule. These results suggest that twice daily administration has similar efficacy and tolerability to thrice daily administration and is an acceptable alternative for patients who would benefit from UFT with LV therapy.
Collapse
Affiliation(s)
- P M Hoff
- Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Anthony L, Chester M, Michael S, O’Dorisio TM, O’Dorisio MS. Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14624] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Bellet RE, Ghazal H, Flam M, Drelichman A, Gabrail N, Woytowitz D, Loesch D, Niforos D, Mangione A, Anthony L. A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9109] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9109 Background: The effect of using IV iron sucrose in managing cancer chemotherapy-related anemia has not been previously reported. To investigate this issue, we conducted a randomized study of IV iron sucrose in patients (pts) with cancer chemotherapy-related anemia who completed 8 prior wks of ESA therapy. Methods: This prospective, multicenter, randomized, open label, Phase III clinical trial enrolled 375 pts with chemotherapy induced anemia (Hgb levels = 10.0 g/dL) and was conducted in 2 stages. During Stage I (8-wk duration), pts received treatment with fixed ESA doses (100-mcg of darbepoetin or 40,000 units epoetin wkly or 200 mcg of darbepoetin every other wk). Pts were classified as either ESA responders (= 1 g/dL increase in Hgb) or ESA non-responders with each group randomized (Stage 2) separately to receive either 12 wks of fixed doses of ESA plus up to 1,500 mg of iron sucrose (given in 3 divided doses of up to 500mg) or 12 wks of fixed doses of ESA alone. Laboratories (including iron indices and acute phase reactants), quality of life and adverse events were assessed at baseline and throughout. Results: Iron sucrose plus ESA compared to ESA alone resulted in greater mean maximum Hgb levels and greater number of pts who achieved Hgb increases = 2.0 and ≥ 3.0 g/dl in both prior ESA responders and non-responders. There was also a statistically significant improvement in fatigue and iron stores in the iron sucrose treated pts. Baseline iron status did not predict responsiveness to iron sucrose therapy. Three serious but non-life threatening iron sucrose related adverse events were observed including one case of significant, transient hypotension in a female weighing 50 kg. Conclusions: IV iron sucrose increased Hgb levels and iron stores significantly and is well tolerated in doses up to 500 mg increments in ESA treated patients with cancer chemotherapy- related anemia. IV iron sucrose should be considered in combination with erythropoietic therapy in anemic cancer patients receiving chemotherapy. [Table: see text]
Collapse
Affiliation(s)
- R. E. Bellet
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - H. Ghazal
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - M. Flam
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - A. Drelichman
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - N. Gabrail
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - D. Woytowitz
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - D. Loesch
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - D. Niforos
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - A. Mangione
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | - L. Anthony
- Luitpold Pharmaceuticals, Elkins Park, PA; Kentucky Cancer Clinic, Hazard, KY; Hematology/Oncology Group of Fresno, Fresno, CA; Newland Medical Associates, Southfield, MI; Nashat Cancer Cneter, Canton, OH; Florida Cancer Specialists, Ft. Myers, FL; Oncology/Hematology Associates, Indianapolis, IN; AAI Pharma, Natick, MA; Luitpold, Norristown, PA; LSUHSC New Orleans, New Orleans, LA
| | | |
Collapse
|
21
|
Kvols L, Glusman JE, Hahn EA, Wang E, Öberg K, Anthony L, O’Dorisio TM, de Herder W, Darby CH, Wiedenmann, G. B. The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4558] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4558 Background: Pasireotide is a novel multi-ligand somatostatin analogue with high affinity binding for four of the five somatostatin receptor subtypes (sst1,2,3 and sst5). This Phase II clinical trial showed that pasireotide is effective in controlling the symptoms of diarrhea and flushing in 27% of patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. The impact of pasireotide therapy on health-related quality of life (HRQL) was also evaluated. Methods: Patients in this open-label, multicenter study initially received pasireotide 300 μg sc bid which was escalated to a maximum dose of 1,200 μg sc bid until clinical response was achieved. Data are reported for the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D) instrument. FACIT-D comprises the Functional Assessment of Cancer Therapy-General (FACT-G) score, which measures physical, social, emotional and functional well-being, plus a symptom-specific sub-scale which measures HRQL specific to diarrhea. FACIT-D baseline assessment was obtained on day 1 immediately before dosing, and then monthly thereafter. FACIT-D sub-scale and total scores at baseline and after 1, 2, and 3 months of pasireotide treatment are described by categories of clinical response. Results: 45 patients (mean age 61 years; range 40–83) received treatment, and 44 were eligible for the efficacy and HRQL analyses. Functional well-being scores, symptom-specific scores and total FACIT-D scores of non-responders tended to be lower at baseline and during treatment than those of responders. The three sub-scale and summary FACIT-D scores exhibited relatively stable mean HRQL scores and similar patterns of variability in clinical responders and non- responders through the third month of pasireotide treatment. Conclusions: HRQL was stable during treatment with pasireotide in patients with advanced metastatic disease refractory or resistant to octreotide LAR. Additional work in HRQL study design and evaluation of HRQL endpoints in patients with carcinoid disease is indicated, and will further improve our understanding of quality of life in patients with this disease. [Table: see text]
Collapse
Affiliation(s)
- L. Kvols
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| | - J. E. Glusman
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| | - E. A. Hahn
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| | - E. Wang
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| | - K. Öberg
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| | - L. Anthony
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| | - T. M. O’Dorisio
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| | - W. de Herder
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| | - C. H. Darby
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| | - B. Wiedenmann, G.
- H Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Feinberg School of Medicine, Chicago, IL; University Hospital, Uppsala, Sweden; Louisiana State University Medical Center, New Orleans, LA; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Universitatsklinikum Charité-Virchow-Klinikum, Berlin, Germany; and the Pasireotide Carcinoid Study Group
| |
Collapse
|
22
|
Baker RA, Anthony L, Sanders H. An audit of the quality of a referral document, designed in accordance with Scottish Intercollegiate Guidelines Network, for paediatric exodontia under general anaesthesia. Int J Paediatr Dent 2006; 16:307-8. [PMID: 16759331 DOI: 10.1111/j.1365-263x.2006.00740.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- R A Baker
- South Devon Healthcare NHS Trust, Torquay, Devon, UK.
| | | | | |
Collapse
|
23
|
Kvols L, Wiedenmann B, Oberg K, Glusman JE, O’dorisio TM, De Herder W, Gao B, Arnold R, Anthony L. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4082] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4082 Background: Pasireotide is a novel multiligand somatostatin analogue that exhibits high binding affinity to 4 of 5 somatostatin receptor subtypes: sst1,2,3 and sst5. Compared with octreotide, pasireotide has 30, 5 and 40 times greater affinity for sst1,3 and sst5 receptors respectively and a comparable affinity for sst2. Methods: This was a Phase II, open-label, multicenter study in patients with metastatic carcinoid tumors whose symptoms (diarrhea and flushing) were inadequately controlled by octreotide LAR. Patients had histopathologically confirmed disease, elevated 5-HIAA and/or CgA levels and at least one measurable lesion (excluding bone). Patients initially received pasireotide 300 μg sc bid and escalated to a maximum dose of 1200 μg sc bid every 3 days until clinical response was achieved. Partial response (PR) was defined as a mean of <4 bowel movements (BM)/day with no more than 6 BM on any given day, and a mean of <2 flushing episodes/day for 15 consecutive days on a fixed dose of pasireotide. Complete response (CR) was defined as a mean of ≤3 BM/day, with no more than 3 BM on any given day, and no flushing episodes. Results: Safety data are reported from 45 patients as of September 2005; 44 patients (mean age 61 years) qualified for efficacy assessment. Carcinoid tumors were predominantly of midgut origin. Preliminary efficacy data in controlling symptoms of carcinoid syndrome showed PR in 9 patients (20%) at 600–1200 μg sc bid doses and CR in 2 patients (5%) at the 600 and 900 μg sc bid doses. Objective tumor response in 11 patients showed 9 with stable disease and 2 with progressive disease at 6 months. Adverse events (AEs) were primarily gastrointestinal (GI): abdominal pain (31%) and nausea (27%). Weight loss (22%) and fatigue (22%) were also reported. Most AEs were mild or moderate. Glucose-related AEs (predominantly CTC grade 1–2) were observed in 24% of patients. Most discontinuations were due to GI AEs (n = 6) or lack of therapeutic response. Conclusions: Pasireotide 600–1200 μg sc bid was effective in controlling symptoms of diarrhea and flushing in 25% of patients with metastatic carcinoid tumors inadequately controlled by octreotide LAR. The safety profile of pasireotide is similar to octreotide LAR. [Table: see text]
Collapse
Affiliation(s)
- L. Kvols
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Universitatsklinikum, Berlin, Germany; University Hospital, Uppsala, Sweden; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Philipps-Universitat, Marburg, Germany; Louisiana State University Medical Center, New Orleans, LA
| | - B. Wiedenmann
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Universitatsklinikum, Berlin, Germany; University Hospital, Uppsala, Sweden; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Philipps-Universitat, Marburg, Germany; Louisiana State University Medical Center, New Orleans, LA
| | - K. Oberg
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Universitatsklinikum, Berlin, Germany; University Hospital, Uppsala, Sweden; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Philipps-Universitat, Marburg, Germany; Louisiana State University Medical Center, New Orleans, LA
| | - J. E. Glusman
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Universitatsklinikum, Berlin, Germany; University Hospital, Uppsala, Sweden; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Philipps-Universitat, Marburg, Germany; Louisiana State University Medical Center, New Orleans, LA
| | - T. M. O’dorisio
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Universitatsklinikum, Berlin, Germany; University Hospital, Uppsala, Sweden; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Philipps-Universitat, Marburg, Germany; Louisiana State University Medical Center, New Orleans, LA
| | - W. De Herder
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Universitatsklinikum, Berlin, Germany; University Hospital, Uppsala, Sweden; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Philipps-Universitat, Marburg, Germany; Louisiana State University Medical Center, New Orleans, LA
| | - B. Gao
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Universitatsklinikum, Berlin, Germany; University Hospital, Uppsala, Sweden; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Philipps-Universitat, Marburg, Germany; Louisiana State University Medical Center, New Orleans, LA
| | - R. Arnold
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Universitatsklinikum, Berlin, Germany; University Hospital, Uppsala, Sweden; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Philipps-Universitat, Marburg, Germany; Louisiana State University Medical Center, New Orleans, LA
| | - L. Anthony
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Universitatsklinikum, Berlin, Germany; University Hospital, Uppsala, Sweden; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Iowa, Iowa City, IA; Erasmus Medical Center, Rotterdam, The Netherlands; Philipps-Universitat, Marburg, Germany; Louisiana State University Medical Center, New Orleans, LA
| |
Collapse
|
24
|
Kvols L, Oberg K, de Herder W, Anthony L, Glusman J, Tran LL, Wiedenmann B. Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8024] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Kvols
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Univ Hosp, Uppsala, Sweden; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Louisiana State Univ Medcl Ctr, New Orleans, LA; Novartis Pharmaceuticals Corp, East Hanover, NJ; Univklin Charité-Virchow-Klinikum, Berlin, Germany
| | - K. Oberg
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Univ Hosp, Uppsala, Sweden; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Louisiana State Univ Medcl Ctr, New Orleans, LA; Novartis Pharmaceuticals Corp, East Hanover, NJ; Univklin Charité-Virchow-Klinikum, Berlin, Germany
| | - W. de Herder
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Univ Hosp, Uppsala, Sweden; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Louisiana State Univ Medcl Ctr, New Orleans, LA; Novartis Pharmaceuticals Corp, East Hanover, NJ; Univklin Charité-Virchow-Klinikum, Berlin, Germany
| | - L. Anthony
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Univ Hosp, Uppsala, Sweden; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Louisiana State Univ Medcl Ctr, New Orleans, LA; Novartis Pharmaceuticals Corp, East Hanover, NJ; Univklin Charité-Virchow-Klinikum, Berlin, Germany
| | - J. Glusman
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Univ Hosp, Uppsala, Sweden; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Louisiana State Univ Medcl Ctr, New Orleans, LA; Novartis Pharmaceuticals Corp, East Hanover, NJ; Univklin Charité-Virchow-Klinikum, Berlin, Germany
| | - L.-L. Tran
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Univ Hosp, Uppsala, Sweden; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Louisiana State Univ Medcl Ctr, New Orleans, LA; Novartis Pharmaceuticals Corp, East Hanover, NJ; Univklin Charité-Virchow-Klinikum, Berlin, Germany
| | - B. Wiedenmann
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Univ Hosp, Uppsala, Sweden; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Louisiana State Univ Medcl Ctr, New Orleans, LA; Novartis Pharmaceuticals Corp, East Hanover, NJ; Univklin Charité-Virchow-Klinikum, Berlin, Germany
| |
Collapse
|
25
|
Rosenoff S, Gabrail N, Conklin R, Hohneker J, Berg W, Hedrick J, Warsi G, Benedetto J, Zhu W, Anthony L. A multicenter, randomized trial of long-acting octreotide (LAR) in the treatment of chemotherapy-induced diarrhea (CTID). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Rosenoff
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| | - N. Gabrail
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| | - R. Conklin
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| | - J. Hohneker
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| | - W. Berg
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| | - J. Hedrick
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| | - G. Warsi
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| | - J. Benedetto
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| | - W. Zhu
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| | - L. Anthony
- Oncology and Hematology Associates/US Oncology, Roanoke, VA; Gabrail Cancer Center, Canton, OH; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA
| |
Collapse
|
26
|
Le L, Linares L, Andrews S, Anthony L. Indium-111 pentetreotide therapy in somatostatin receptor expressing neoplasms: Results from clinical practice. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Le
- LSUHSC New Orleans, New Orleans, LA
| | | | | | | |
Collapse
|
27
|
Sarradell J, Pérez AM, Comba E, Pereira N, Anthony L, Andrada M, Segalés J. [Pathological findings in pigs affected by the postweaning multisystemic wasting syndrome in Argentina]. Rev Argent Microbiol 2004; 36:118-24. [PMID: 15559193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023] Open
Abstract
Postweaning multisystemic wasting syndrome was first described in Canada in 1991 and at present an increasing number of cases has been diagnosed worldwide. In Argentina the first cases of PMWS were reported recently. Forty eight 5 to 12 week old pigs with signs characteristic of PMWS from 19 farms were studied. Although the real distribution of the virus in our country is not known it was observed an increasing number of farms with PMWS distributed in the major producing provinces. The histopathology was an important tool in diagnosis of suspicious cases of PMWS with the observation of different degrees of lesion. In the studied animals, the secondary infections, either by opportunistic pathogens or secondary bacteria could be important.
Collapse
Affiliation(s)
- J Sarradell
- Facultad de Cs. Veterinarias-Ov. Lagos y Ruta 33, (2170) Casilda, Argentina.
| | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
It is clear that multiple sites of interaction exist between sigmas and core subunits, likely reflecting the changing pattern of interactions that occur sequentially during the complex process of holoenzyme formation, open promoter formation, and initiation of transcription. Recent studies have revealed that a major site of interaction of Escherichia coli sigma factors is the amino acid 260-309 coiled-coil region of the beta' subunit of core RNA polymerase. This region of beta' interacts with region 2.1-2.2 of sigma(70). Binding of this region of beta' to sigma(70) triggers a conformational change in sigma that allows it to bind to a -10 nontemplate promoter DNA strand oligonucleotide.
Collapse
Affiliation(s)
- R R Burgess
- McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, 1400 University Avenue, Madison, WI 53706, USA.
| | | |
Collapse
|
29
|
Artsimovitch I, Svetlov V, Anthony L, Burgess RR, Landick R. RNA polymerases from Bacillus subtilis and Escherichia coli differ in recognition of regulatory signals in vitro. J Bacteriol 2000; 182:6027-35. [PMID: 11029421 PMCID: PMC94735 DOI: 10.1128/jb.182.21.6027-6035.2000] [Citation(s) in RCA: 86] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Adaptation of bacterial cells to diverse habitats relies on the ability of RNA polymerase to respond to various regulatory signals. Some of these signals are conserved throughout evolution, whereas others are species specific. In this study we present a comprehensive comparative analysis of RNA polymerases from two distantly related bacterial species, Escherichia coli and Bacillus subtilis, using a panel of in vitro transcription assays. We found substantial species-specific differences in the ability of these enzymes to escape from the promoter and to recognize certain types of elongation signals. Both enzymes responded similarly to other pause and termination signals and to the general E. coli elongation factors NusA and GreA. We also demonstrate that, although promoter recognition depends largely on the sigma subunit, promoter discrimination exhibited in species-specific fashion by both RNA polymerases resides in the core enzyme. We hypothesize that differences in signal recognition are due to the changes in contacts made between the beta and beta' subunits and the downstream DNA duplex.
Collapse
Affiliation(s)
- I Artsimovitch
- Department of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
| | | | | | | | | |
Collapse
|
30
|
Abstract
Allylation of aldehydes by an allyl-transfer reaction from the gamma-adducts of homoallylic alcohols has been successfully carried out to give the corresponding alpha-adducts regiospecifically. The reaction proceeds via a hemiacetal (11), derived from an aldehyde and the homoallylic alcohol, followed by a six-membered cyclic transition state (2-oxonia[3.3]-sigmatropic rearrangement) in the presence of a Lewis acid. Moreover, the gamma-adducts are restructured into the corresponding alpha-adducts via a similar transition state by an acid catalyst, in which chirality in both anti- and syn-gamma-adducts is stereospecifically transferred to the corresponding E- and Z-alpha-adducts, respectively, with > 98% ee.
Collapse
Affiliation(s)
- J Nokami
- Faculty of Engineering, Okayama University of Science, Japan.
| | | | | |
Collapse
|
31
|
Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600-6. [PMID: 10080605 DOI: 10.1200/jco.1999.17.2.600] [Citation(s) in RCA: 297] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
PURPOSE Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated long-acting formulation (LAR) of octreotide acetate has been developed for once-monthly intramuscular dosing. PATIENTS AND METHODS A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome. Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population. RESULTS Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons). Control of stool frequency was similar in all treatment groups. Flushing episodes were best controlled in the 20-mg LAR and SC groups; the 10-mg LAR treatment was least effective in the control of flushing. Treatment was well tolerated by patients in all four groups. CONCLUSION Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of octreotide LAR is recommended. Supplemental SC octreotide is needed for approximately 2 weeks after initiation of octreotide LAR treatment. Occasional rescue SC injections may be required for possibly 2 to 3 months until steady-state octreotide levels from the LAR formulation are achieved.
Collapse
Affiliation(s)
- J Rubin
- Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Schonfeld WH, Eikin EP, Woltering EA, Modlin IM, Anthony L, Villa KF, Zagari M. The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma. Int J Technol Assess Health Care 1998; 14:514-25. [PMID: 9780538 DOI: 10.1017/s0266462300011491] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Markov modeling was used to evaluate the cost-effectiveness of octreotide in treating carcinoid syndrome and VIPoma. For each condition, using octreotide was associated with doubled survival time. Octreotide was cost-effective for treating carcinoid tumor ($752 per additional year of life, two additional years on average), and cost saving for VIPoma.
Collapse
|
33
|
Nagel LJ, Anthony L, Okamoto JK, Fultz B. An experimental study of the difference in vibrational entropy between ordered and disordered Fe3A1. ACTA ACUST UNITED AC 1997. [DOI: 10.1007/bf02665810] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Marlowe RL, Lukan AM, Lee SA, Anthony L, Chandrasekaran R, Rupprecht A. Differential scanning calorimetric and X-ray study of the binding of the water of primary hydration to calf-thymus DNA. J Biomol Struct Dyn 1996; 14:373-9. [PMID: 9016414 DOI: 10.1080/07391102.1996.10508132] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Differential scanning calorimetry has been used to study the thermal properties of hydrated films of calf-thymus Na-, K- and CsDNA between 20 and 320 degrees C. A broad endothermic transition near 75 degrees C and a sharp exothermic transition near 240 degrees C are observed. The broad transition is due to the dehydration of the DNA, while the exothermic transition is due to pyrolysis of the sample. the peak temperatures of both transitions increase as the scan rate is increased. Based on a Kissinger analysis, the net activation energy for the desorption of the primary water of hydration is about 0.6 eV while that for the pyrolysis is about 1.9 eV. X-ray diffraction patterns suggest that heating the DNA films to 180 degrees C once does not, but thrice does, destroy their structural ordering.
Collapse
Affiliation(s)
- R L Marlowe
- Department of Physics & Astronomy, University of Tennessee at Chattanooga 37403, USA
| | | | | | | | | | | |
Collapse
|
35
|
Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 1996; 14:2242-9. [PMID: 8708713 DOI: 10.1200/jco.1996.14.8.2242] [Citation(s) in RCA: 109] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
PURPOSE To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in preventing cisplatin-induced nausea and vomiting. PATIENTS AND METHODS Cancer patients (n = 609) receiving first-course cisplatin chemotherapy were randomized to one of three treatments: 1.8 or 2.4 mg/kg dolasetron mesylate salt (equivalent to 1.3 and 1.8 mg/kg dolasetron base, respectively) or 32 mg ondansetron. Each treatment was infused over 15 minutes, 30 minutes before cisplatin administration. Patients were stratified to cisplatin doses of > or = 70 and less than 91 mg/m2 (n = 368) or > or = 91 mg/m2 (n = 241), administered over < or = 3 hours. Protocol-defined efficacy criteria included complete response (zero emetic episodes and no rescue medication), major response (1 to 2 emetic episodes and no rescue medication), and patients' report of nausea severity and satisfaction recorded on a 100-mm visual analog scale (VAS). RESULTS The three treatments met protocol-specified criteria for equivalence. Complete response rates for dolasetron mesylate 1.8 mg/kg, 2.4 mg/kg, and ondansetron, respectively, were 49.2%, 45.6%, and 50.4% for patients in the lower cisplatin stratum (mean, 74.7 mg/m2) and 36.8%, 31.3%, and 31.8% in the higher cisplatin stratum (mean, 100.6 mg/m2). No significant differences were observed in the extent of nausea with either dolasetron dose compared with ondansetron. Less nausea was noted with 1.8 mg/kg dolasetron compared with the 2.4 mg/kg dose (P = .044) All three antiemetic treatments were well tolerated. Asymptomatic electrocardiogram changes were recorded with both dolasetron and ondansetron. CONCLUSION A single IV dose of dolasetron mesylate (1.8 or 2.4 mg/kg) has comparable safety and efficacy to a single 32-mg IV dose of ondansetron in patients receiving cisplatin chemotherapy.
Collapse
Affiliation(s)
- P Hesketh
- Boston University Medical Center, MA, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Fultz B, Anthony L, Nagel LJ, Nicklow RM, Spooner S. Phonon densities of states and vibrational entropies of ordered and disordered Ni3Al. Phys Rev B Condens Matter 1995; 52:3315-3321. [PMID: 9981449 DOI: 10.1103/physrevb.52.3315] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
38
|
Fultz B, Anthony L, Robertson JL, Nicklow RM, Spooner S, Mostoller M. Phonon modes and vibrational entropy of mixing in Fe-Cr. Phys Rev B Condens Matter 1995; 52:3280-3285. [PMID: 9981445 DOI: 10.1103/physrevb.52.3280] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
39
|
Anthony L, Nagel LJ, Okamoto JK, Fultz B. Magnitude and origin of the difference in vibrational entropy between ordered and disordered Fe3Al. Phys Rev Lett 1994; 73:3034-3037. [PMID: 10057265 DOI: 10.1103/physrevlett.73.3034] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
40
|
|
41
|
Abstract
To further investigate the antineoplastic efficacy and safety of somatostatin analogues, 2 trials were performed. Octreotide, SMS 201-995 (Sandostatin), was escalated in doses ranging from 1,500 micrograms to 6,000 micrograms daily in 14 patients with carcinoid. Somatuline, (BIM 23014C, Angiopeptin, Lanreotide) was given in doses ranging from 2,250 micrograms to 9,000 micrograms daily to 13 neuroendocrine patients (6 carcinoid, 2 atypical carcinoid, 3 pancreatic islet cell and 2 small cell lung cancer patients). All patients successfully completed dose escalations without significant adverse effects and were evaluable for toxicity. The dose limiting side-effect of octreotide was the injection volume. No dose limiting adverse effects have been observed with somatuline. Carcinoid syndrome symptoms were better controlled with higher octreotide doses. Thirteen patients were evaluable for octreotide's antitumor efficacy with a partial response observed in 4 (31%), stable disease in 2 and progressive disease in 7 patients. Radiographic changes of increased tumor necrosis occurred in 5 patients and was independent of response. Somatuline resulted in a partial response in 4 patients (2 carcinoids, 1 gastrinoma and 1 small cell lung cancer) (31%), stable disease in 1 atypical carcinoid, and progressive disease in 8 (4 carcinoid, 1 atypical carcinoid, 2 islet cell and 1 multi-drug resistant small cell lung cancer). Six of the 8 carcinoid patients had radiographic changes of increased necrosis. Dose escalation of somatostatin analogues is well tolerated and may be associated with antitumor activity in some neuroendocrine neoplasms.
Collapse
Affiliation(s)
- L Anthony
- Department of Medicine and Radiology, Vanderbilt University, Nashville, TN 37232-5536
| | | | | | | | | | | | | |
Collapse
|
42
|
Hinds P, Norville R, Anthony L, Briscoe B, Gattuso J, Quargnenti A, Riggins M, Walters L, Wentz T, Scarbrough K. Pediatric cancer nursing research priorities: a Delphi study. J Pediatr Oncol Nurs 1990; 7:51-2. [PMID: 2194503 DOI: 10.1177/104345429000700205] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
|
43
|
Smith S, Anthony L, Roberts LJ, Oates JA, Pincus T. Resolution of musculoskeletal symptoms in the carcinoid syndrome after treatment with the somatostatin analog octreotide. Ann Intern Med 1990; 112:66-8. [PMID: 2293820 DOI: 10.7326/0003-4819-112-1-66] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Affiliation(s)
- S Smith
- Vanderbilt University School of Medicine, Nashville, Tennessee
| | | | | | | | | |
Collapse
|
44
|
Abstract
We investigated the effect of debrisoquin on propranolol metabolism in six normal subjects who were extensive metabolizers of debrisoquin. Each subject was studied on two occasions. On the first occasion, each subject received oral propranolol (80 mg) alone; on the second occasion, 7 days later, each subject received a dose of propranolol (80 mg) 30 minutes after the administration of oral debrisoquin (40 mg). Oral propranolol clearance was reduced 33% +/- 16% (p less than 0.05) by the administration of debrisoquin. As predicted, the 4-hydroxypropranolol partial metabolic clearance was significantly (p less than 0.05) inhibited by debrisoquin. However, the side-chain oxidation pathway, as measured by naphthoxylactic acid, was also significantly (p less than 0.05) inhibited by debrisoquin. Debrisoquin administration did not change the renal clearance of any of the metabolites. These data support the usefulness of the in vivo inhibition model in the prediction of cosegregation of routes of metabolism. However, for propranolol, pathways of its metabolism that are not thought to cosegregate with debrisoquin was also inhibited.
Collapse
Affiliation(s)
- L Anthony
- Department of Medicine, Vanderbilt University, Nashville, TN 37232
| | | | | |
Collapse
|
45
|
Hande K, Anthony L, Hamilton R, Bennett R, Sweetman B, Branch R. Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit. Cancer Res 1988; 48:1829-34. [PMID: 3349461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Isolated livers from male Sprague-Dawley rats were perfused at 20 ml/min for 3 h at 37 degrees C with 100 ml of an oxygenated, recirculating solution of 20% rat blood in Krebs bicarbonate buffer containing 20 micrograms/ml [3H]etoposide. Ninety % of administered radioactivity was eliminated in bile over a 3-h collection period. The clearance of etoposide was 3.56 ml/min indicating that, in the rat, it is not highly extracted. Its clearance is, therefore, independent of hepatic blood flow. Etoposide was both excreted into the bile and metabolized by the liver. Perfusate and bile samples analyzed by reverse-phase high-performance liquid chromatography techniques were found to contain three peaks of radioactivity. Positive and negative ion fast atom bombardment mass spectrometry identified the first two peaks as etoposide glucuronides and the third peak as parent drug. Following the i.v. administration of etoposide to rabbits, etoposide glucuronide was also identified in rabbit urine. The recovery of etoposide both from rabbit urine and rat bile was increased by preincubation with glucuronidase. However, the glucuronides were relatively resistant to the action of glucuronidase and showed varying sensitivity to the type of glucuronidase and the reaction conditions used. These studies document the presence of etoposide glucuronide as an etoposide metabolite in two mammalian species and suggest that previous clinical studies using beta-glucuronidase to quantitate glucuronide formation may have underestimated this metabolite due to its relative resistance to some glucuronidase preparations.
Collapse
Affiliation(s)
- K Hande
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| | | | | | | | | | | |
Collapse
|
46
|
Hande K, Combs G, Swingle R, Combs GL, Anthony L. Effect of cimetidine and ranitidine on the metabolism and toxicity of hexamethylmelamine. Cancer Treat Rep 1986; 70:1443-5. [PMID: 3098418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
In a rat model, doses of 20-120 mg/kg of cimetidine prolonged in a dose-related manner the half-life of hexamethylmelamine by 29%-80%, while doses of 1-25 mg/kg of ranitidine did not. Administration of 120 mg/kg of cimetidine with a single 350-mg/kg dose of hexamethylmelamine increased toxicity from LD30 to LD75 (P = 0.005). When combined with 25 mg/kg of ranitidine, a statistically insignificant (P = 0.16) 15% increase in hexamethylmelamine toxicity was noted. These studies indicate that cimetidine but not ranitidine increases the toxicity of hexamethylmelamine through inhibition of microsomal metabolism.
Collapse
|
47
|
|
48
|
Abstract
To study the effect of age on prediction of hearing level from the acoustic reflex, we compared reflex prediction with the actual hearing level in 505 patients. The following three age groups were defined: 130 children aged 2 to 12 years; 158 young adults aged 20 to 40 years; and 217 old adults aged 60 to 90 years. Prediction was substantially more accurate in the children's group than in either adult group.
Collapse
|
49
|
|